IGM Biosciences IncNASDAQ:IGMS
- LAST PRICE8.2200
- TODAY'S CHANGE (%)0.0100 (0.1218%)
- Bid / Lots7.9000/ 17
- Ask / Lots8.4000/ 2
- Open / Previous Close8.1100 / 8.2100
- Day Range
- 52 Week Range
- Volume84,446
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IGMS |
|---|---|---|
| 09:32 ET | 436 | 8.11 |
| 09:36 ET | 487 | 8.0073 |
| 09:41 ET | 800 | 8.175 |
| 09:57 ET | 243 | 8.13 |
| 10:08 ET | 100 | 8.12 |
| 10:26 ET | 910 | 8.23 |
| 10:39 ET | 200 | 8.3831 |
| 10:44 ET | 1031 | 8.38 |
| 10:46 ET | 6000 | 8.37 |
| 10:48 ET | 1000 | 8.375 |
| 10:50 ET | 100 | 8.375 |
| 11:06 ET | 600 | 8.36 |
| 11:09 ET | 100 | 8.36 |
| 11:20 ET | 1169 | 8.223 |
| 11:26 ET | 100 | 8.275 |
| 11:36 ET | 100 | 8.285 |
| 12:02 ET | 400 | 8.26 |
| 12:03 ET | 100 | 8.255 |
| 12:07 ET | 290 | 8.3 |
| 12:09 ET | 100 | 8.255 |
| 12:16 ET | 1100 | 8.21 |
| 12:21 ET | 200 | 8.2 |
| 12:39 ET | 100 | 8.19 |
| 12:41 ET | 600 | 8.2 |
| 12:43 ET | 100 | 8.17 |
| 12:50 ET | 900 | 8.13 |
| 01:21 ET | 100 | 8.155 |
| 01:30 ET | 200 | 8.07 |
| 01:32 ET | 1000 | 8.06 |
| 01:33 ET | 200 | 8.075 |
| 01:35 ET | 200 | 8.1 |
| 01:42 ET | 406 | 8.09 |
| 01:46 ET | 200 | 8.125 |
| 02:00 ET | 1500 | 8.055 |
| 02:04 ET | 100 | 8.06 |
| 02:09 ET | 1243 | 8.0807 |
| 02:13 ET | 500 | 8.08 |
| 02:15 ET | 600 | 8.08 |
| 02:22 ET | 200 | 8.09 |
| 02:24 ET | 300 | 8.09 |
| 02:26 ET | 200 | 8.09 |
| 02:33 ET | 3400 | 8.11 |
| 02:36 ET | 1040 | 8.08 |
| 02:44 ET | 100 | 8.05 |
| 02:47 ET | 500 | 8.085 |
| 02:49 ET | 300 | 8.085 |
| 03:00 ET | 399 | 8.06 |
| 03:03 ET | 100 | 8.11 |
| 03:09 ET | 100 | 8.085 |
| 03:16 ET | 100 | 8.085 |
| 03:20 ET | 300 | 8.085 |
| 03:21 ET | 1007 | 8.07 |
| 03:25 ET | 300 | 8.08 |
| 03:27 ET | 200 | 8.095 |
| 03:30 ET | 991 | 8.08 |
| 03:32 ET | 4023 | 8.08 |
| 03:36 ET | 600 | 8.1 |
| 03:38 ET | 600 | 8.105 |
| 03:39 ET | 1500 | 8.14 |
| 03:43 ET | 200 | 8.14 |
| 03:45 ET | 2099 | 8.15 |
| 03:48 ET | 1400 | 8.21 |
| 03:50 ET | 221 | 8.205 |
| 03:52 ET | 458 | 8.2 |
| 03:54 ET | 2331 | 8.22 |
| 03:56 ET | 726 | 8.22 |
| 03:57 ET | 600 | 8.235 |
| 03:59 ET | 14984 | 8.22 |
May 29, 2024
IGM Biosciences to Present at the Jefferies Healthcare Conference, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 24, 2024
DJ IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 6:31AM ET on Friday May 24, 2024 by Dow Jones
6:31AM ET on Friday May 24, 2024 by Dow Jones
May 9, 2024
DJ IGM Biosciences Price Target Maintained With a $20.00/Share by Wedbush, from 8:59AM ET on Thursday May 09, 2024 by Dow Jones
8:59AM ET on Thursday May 09, 2024 by Dow Jones
May 8, 2024
*DJ IGM Biosciences 1Q Loss/Shr 83c >IGMS, from 4:10PM ET on Wednesday May 08, 2024 by Dow Jones
4:10PM ET on Wednesday May 08, 2024 by Dow JonesIGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update, from 4:10PM ET on Wednesday May 08, 2024 by Dow Jones
4:10PM ET on Wednesday May 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IGM Biosciences Inc | 491.7M | -1.9x | --- |
Fulcrum Therapeutics Inc | 487.9M | -5.2x | --- |
Cabaletta Bio Inc | 491.9M | -6.1x | --- |
Kalvista Pharmaceuticals Inc | 492.3M | -3.7x | --- |
Neurogene Inc | 488.1M | -8.3x | --- |
Aerovate Therapeutics Inc | 502.7M | -6.8x | --- |
Company Information
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Contact Information
- Headquarters
- 325 E Middlefield RdMOUNTAIN VIEW, CA, United States 94043-4003
- Phone
- 650-965-7873
- Fax
- 302-655-5049
Executives
- Chief Executive Officer, Director
- Fred Schwarzer
- Chief Financial Officer
- Misbah Tahir
- Chief Scientific Officer
- Bruce Keyt
- Chief Business Officer
- Lisa Decker
- Chief Commercial Officer
- George Gauthier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $477.5M |
|---|---|
Revenue (TTM) | $2.1M |
Shares Outstanding | 59.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.22 |
EPS | $-4.31 |
Book Value | $3.46 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 226.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,063.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
